Marc Beer is a renowned specialist in the pharmaceuticals and biotechnology sector. He is a name to reckon with in this sector. With more than 25 years of experience in the development of diagnostic and pharmaceutical devices to transform the medical care sector, he embarked on a new project to develop pharmaceutical devices for the treatment of pelvic floor disorders. He has a proven track record of success and dynamic leadership. While he was the CEO of ViaCell, a well-established biotech firm, he helped the firm grow dramatically to employing more than 300 recruits. He also was very instrumental in the success of the various projects started by ViaCell.
Before ViaCell, Marc Beer served in multiple other organizations in different capacities. His leadership capabilities are unquestionable and skill unparalleled. He served in Genzyme as the president of global marketing. In this role, he attained great success that led to global recognition of the company. He was responsible for the commercial launch of several advanced medical care products for the treatment of rare diseases on a worldwide scale. Marc Beer also served as a sales and marketing head in Abbot Laboratories in the department of pharmaceuticals and diagnostics. He also serves in many boards of directors in the advisory role.
Since joining the industry, Marc Beer had a vision of creating solutions to complex problems. Through innovative technology, he has always wanted to improve the quality of medical care as well as curb the health problems affecting high populations globally. In this regard, Marc Beer pinpointed pelvic floor disorders a health problem that affects more than 200 million women worldwide. Recently he raised $42 million to fund Renovia Inc. a medtech startup based out of Boston. The firm will utilize the funds to develop modern, advanced, and more efficient diagnostic products to combat pelvic floor disorders such as urinary incontinence, pelvic floor dysfunction, and pelvic pain, among others. Marc Has received overwhelming support which is a gesture of trust that investors have in him to attain his goals with the firm.
Marc Beer never disappoints. Through Renovia Inc. and the massive funding he received, great results have already started showing. In April 2018,launched Renovia’s first product, Leva, from approval from the FDA. This is the first of the four products that the firm is developing in a mission to provide a long-lasting solution to pelvic floor disorders while restoring pelvic floor muscles. Also, the firm seeks to develop highly efficient products to lower the overall cost of medical care. With these advanced diagnosis products, the company believes it can successfully help patients reclaim the control of their pelvic floor muscles as a long-term and the most effective way to ensure pelvic floor disorders are addressed thoroughly. Learn more: https://www.cnbc.com/video/2013/01/23/aegerion-ceo-on-promise-of-biopharma.html